Arnaud Marchant
Overview
Explore the profile of Arnaud Marchant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
141
Citations
4043
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munoz F, Avila Aguero M, Cutland C, Dinleyici E, Eckert L, Giles M, et al.
Pediatr Infect Dis J
. 2025 Feb;
44(2S):S2-S8.
PMID: 39951063
No abstract available.
2.
Carpenter M, Shrestha S, Bharadwaj P, Concetta C, Sharma S, Weiner J, et al.
Hum Immunol
. 2025 Jan;
86(2):111247.
PMID: 39889319
Donor Specific Antibodies (DSAs) are associated with a higher risk of Antibody Mediated Rejection (AMR). However, not all DSAs are pathogenic, and patients that raise DSAs have a wide spectrum...
3.
Khandaker S, Sharma S, Hall T, Lim S, Lehtonen J, Leung S, et al.
J Infect Dis
. 2024 Dec;
231(2):e456-e467.
PMID: 39692506
Background: Significant disparities in group B Streptococcus (GBS) colonization and neonatal disease rates have been documented across different geographic regions. For example, Bangladesh reports notably lower rates as compared with...
4.
Gemander N, Kemlin D, Depickere S, Kelkar N, Sharma S, Pannus P, et al.
Vaccine
. 2024 Nov;
44:126544.
PMID: 39608249
Background: Clinical risk factors of deficient immune responses to COVID-19 mRNA vaccination in SARS-CoV-2 naive hemodialysis recipients (HDR) have already been identified. Clinical factors influencing hybrid immunity induced by SARS-CoV-2...
5.
Hederman A, Remmel C, Sharma S, Natarajan H, Weiner J, Wrapp D, et al.
J Clin Invest
. 2024 Aug;
134(20).
PMID: 39207860
BACKGROUNDMost humans have been infected with cytomegalovirus (CMV) by midlife without clinical signs of disease. However, in settings in which the immune system is undeveloped or compromised, the virus is...
6.
Etienne I, Kemlin D, Gemander N, Olislagers V, Waegemans A, Dhondt E, et al.
J Heart Lung Transplant
. 2024 Aug;
43(11):1857-1860.
PMID: 39134165
Lung transplant recipients (LTRs) are susceptible to severe Coronavirus Disease 2019 (COVID-19) and had lower immune responses to primary severe acute respiratory syndrome-related to coronavirus 2 (SARS-CoV-2) vaccination as compared...
7.
Verhasselt V, Marchant A, Kollmann T
J Mol Biol
. 2024 Aug;
436(19):168718.
PMID: 39094783
No abstract available.
8.
Functional and epigenetic changes in monocytes from adults immunized with an AS01-adjuvanted vaccine
Bechtold V, Smolen K, Burny W, de Angelis S, Delandre S, Essaghir A, et al.
Sci Transl Med
. 2024 Jul;
16(758):eadl3381.
PMID: 39083587
The adjuvant AS01 plays a key role in the immunogenicity of several approved human vaccines with demonstrated high efficacy. Its adjuvant effect relies on activation of the innate immune system....
9.
Steenackers K, Hanning N, Bruckers L, Desombere I, Marchant A, Arien K, et al.
Vaccine
. 2024 Jul;
42(25):126117.
PMID: 39019657
Background: To overcome supply issues of COVID-19 vaccines, this partially single blind, multi-centric, vaccine trial aimed to evaluate humoral immunogenicity using lower vaccine doses, intradermal vaccination, and heterologous vaccine schedules....
10.
Innovative approaches for vaccine trials as a key component of pandemic preparedness - a white paper
Bethe U, Pana Z, Drosten C, Goossens H, Konig F, Marchant A, et al.
Infection
. 2024 Jul;
52(6):2135-2144.
PMID: 39017997
Background: WHO postulates the application of adaptive design features in the global clinical trial ecosystem. However, the adaptive platform trial (APT) methodology has not been widely adopted in clinical research...